跳至主要内容
临床试验/EUCTR2011-003572-36-GB
EUCTR2011-003572-36-GB进行中(未招募)1 期

The role of GLP-1 analogues in reducing reperfusion injury after acute stroke in patients with impaired swallowing. - Liraglutide after Acute Stroke Trial (LAST).

Royal Devon & Exeter NHS Foundation Trust0 个研究点目标入组 40 人开始时间: 2011年12月6日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Patients over the age of 18 years, presenting within 6 hours of an acute stroke who are able to consent or have next of kins who can provide assent and are planned to be placed nil by mouth for at least 12 hours.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 20
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 20

排除标准

  • Inability to provide informed consent or inability to contact a relative or carer who can provide assent. Stroke as a result of an intra-cerebral bleed. Pregnancy and breast feeding. Liver impairment, Type I diabetes, Patients who are on insulin, Sulphonylurea therapy or other GLP-1 treatment, Hypersensitivity to Liraglutide Other contraindication for the use of Liraglutide (as per SmPC).

研究者

相似试验